<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05047627</url>
  </required_header>
  <id_info>
    <org_study_id>AWD00010555</org_study_id>
    <nct_id>NCT05047627</nct_id>
  </id_info>
  <brief_title>Digital Intervention to Treat Anxiety and Depression Among Persons Receiving Treatment for Opioid Use Disorder</brief_title>
  <official_title>Digital Intervention to Treat Anxiety and Depression Among Persons Receiving Treatment for Opioid Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trustees of Dartmouth College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trustees of Dartmouth College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The majority of opioid users meet criteria for anxiety and depressive disorders, but most&#xD;
      substance use disorder treatment programs do not offer treatment for co-occurring mental&#xD;
      health problems. Anxiety and depression may also be directly linked to opioid use itself.&#xD;
      Although treatments have been developed for anxiety and depressive symptoms for opioid users&#xD;
      within face-to-face settings, few treatment facilities offer these in-person interventions&#xD;
      due to their high cost and time burden. Given the deficits in research on treatments for&#xD;
      anxiety and depression among those with opioid use disorder, the current research will&#xD;
      examine the efficacy of a digital intervention designed to treat anxiety and depressive&#xD;
      symptoms by augmenting the state of the science medication-based opioid use disorder&#xD;
      treatment. Over the course of the proposed study, the research team will design and test the&#xD;
      feasibility and acceptability of a standalone mobile intervention designed to treat persons&#xD;
      receiving medication treatment for opioid use disorder. Participants receiving medication&#xD;
      treatment for opioid use disorder will be randomized to receive a digital intervention to&#xD;
      treat anxiety and depression or care as usual for a total of four weeks. The overarching goal&#xD;
      of the proposed work is to test the feasibility and acceptability of the proposed mobile&#xD;
      intervention. The Investigators will also explore the preliminary efficacy by examining&#xD;
      reductions in anxiety and depressive symptoms and opioid cravings and use. This work could&#xD;
      lead to a low-cost scalable solution to augment gold-standard treatment as usual in opioid&#xD;
      use disorder by decreasing levels of comorbidity of anxiety and depressive disorders, thereby&#xD;
      ultimately improving the outcomes of opioid use disorder itself.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study team will recruit a population of 60 adults who are receiving medication treatment&#xD;
      for OUD from an online study based on Google Adwords, Reddit, and Facebook advertisements as&#xD;
      online recruitment has been shown to be a viable and cost-effective recruitment method for&#xD;
      opioid users. The total sample size may be expanded if recruitment costs are lower than&#xD;
      expected.&#xD;
&#xD;
      Participants will complete self-report assessments on their anxiety symptoms, depressive&#xD;
      symptoms, opioid cravings, and opioid use behaviors. Participants will be randomized to a&#xD;
      smartphone-based digital intervention or waitlist control condition. The digital intervention&#xD;
      will be designed to treat participants' anxiety and depressive symptoms, and participants&#xD;
      will be asked to use the intervention four times per week for four weeks (16 digital&#xD;
      sessions).The smartphone intervention will also collect passive sensing data continuously&#xD;
      during the 4 week period. Participants will complete post measures and one-month follow-up&#xD;
      measures on anxiety symptoms, depressive symptoms, opioid cravings, and opioid use behaviors.&#xD;
      The urine drug screen will be mailed to participants. Participants will also be asked to&#xD;
      complete five urine tests to detect substance use (amphetamines, barbiturates,&#xD;
      benzodiazepines, cocaine, ecstasy, marijuana, methamphetamine, opioids, oxycodone, and pcp)&#xD;
      across the study (1 at pre-digital intervention, 1 during the digital intervention, 1&#xD;
      post-digital intervention, 1 between post and follow-up of the digital intervention, and 1 at&#xD;
      the 1-month follow-up of the digital intervention). Participants will be instructed when to&#xD;
      complete each urine test and will be asked to take a photo of the back the label of each test&#xD;
      showing the results to the experimenters and to text these photos to a Google Voice Number&#xD;
      maintained by the experimenters.&#xD;
&#xD;
      Thus, this proposal seeks to address a crucial deficit in the availability of treatments for&#xD;
      anxiety and depressive disorders among persons with OUD to ultimately augment treatment for&#xD;
      OUD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in anxiety symptoms as assessed by Generalized Anxiety Disorder- Q-IV Scale</measure>
    <time_frame>at baseline, up to 3 days after enrollment</time_frame>
    <description>Assesses anxiety symptoms. Possible GAD-Q-IV scores range from 0 to 12, with higher scores representing greater GAD symptom severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in anxiety symptoms as assessed by Generalized Anxiety Disorder- Q-IV Scale</measure>
    <time_frame>4 weeks after enrollment</time_frame>
    <description>Assesses anxiety symptoms. Possible GAD-Q-IV scores range from 0 to 12, with higher scores representing greater GAD symptom severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in anxiety symptoms as assessed by Generalized Anxiety Disorder- Q-IV Scale</measure>
    <time_frame>8 weeks from enrollment</time_frame>
    <description>Assesses anxiety symptoms. Possible GAD-Q-IV scores range from 0 to 12, with higher scores representing greater GAD symptom severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in depressive symptoms as assessed by Patient Health Questionnaire-9</measure>
    <time_frame>at baseline, up to 3 days after enrollment</time_frame>
    <description>Assesses depressive symptoms, the PHQ-9 score can range from 0 to 27, since each of the 9 items can be scored from 0 (not at all) to 3 (nearly every day)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in depressive symptoms as assessed by Patient Health Questionnaire-9</measure>
    <time_frame>4 weeks after enrollment</time_frame>
    <description>Assesses depressive symptoms, the PHQ-9 score can range from 0 to 27, since each of the 9 items can be scored from 0 (not at all) to 3 (nearly every day)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in depressive symptoms as assessed by Patient Health Questionnaire-9</measure>
    <time_frame>8 weeks from enrollment</time_frame>
    <description>Assesses depressive symptoms, the PHQ-9 score can range from 0 to 27, since each of the 9 items can be scored from 0 (not at all) to 3 (nearly every day)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive Test for Opioids</measure>
    <time_frame>at baseline, up to 3 days after enrollment</time_frame>
    <description>urine tests will detect substance use in participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive Test for Opioids</measure>
    <time_frame>2 weeks after enrollment</time_frame>
    <description>urine tests will detect substance use in participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive Test for Opioids</measure>
    <time_frame>4 weeks after enrollment</time_frame>
    <description>urine tests will detect substance use in participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive Test for Opioids</measure>
    <time_frame>6 weeks after enrollment</time_frame>
    <description>urine tests will detect substance use in participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive Test for Opioids</measure>
    <time_frame>8 weeks after enrollment</time_frame>
    <description>urine tests will detect substance use in participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid Dependency using the Rapid Opioid Dependence Screen</measure>
    <time_frame>at baseline, up to 3 days after enrollment</time_frame>
    <description>The RODS is an eight-item questionnaire inquiring about tolerance; withdrawal; unintended dosage or duration of use; persistent desire and unsuccessful quit attempts; time spent obtaining using and recovering from opioid use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Dependency using the Opioid Craving Scale</measure>
    <time_frame>at baseline, up to 3 days after enrollment</time_frame>
    <description>The Opioid Craving Scale measures opioid cravings using three questions: (1) &quot;How much do you currently crave opiates&quot; (0 Not at all - 10 Extremely).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difficulties in emotion regulation using the Modified Difficulties in Emotion Regulation Scale (DERS)</measure>
    <time_frame>at baseline, up to 3 days after enrollment</time_frame>
    <description>Measures difficulties in emotion regulation with 21 items and a 5 point Likert scale (1 almost never - 5 almost always)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difficulties in emotion regulation using the Modified Difficulties in Emotion Regulation Scale (DERS)</measure>
    <time_frame>4 weeks after enrollment</time_frame>
    <description>Measures difficulties in emotion regulation with 21 items and a 5 point Likert scale (1 almost never - 5 almost always)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difficulties in emotion regulation using the Modified Difficulties in Emotion Regulation Scale (DERS)</measure>
    <time_frame>8 weeks after enrollment</time_frame>
    <description>Measures difficulties in emotion regulation with 21 items and a 5 point Likert scale (1 almost never - 5 almost always)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self Regulation Scale</measure>
    <time_frame>at baseline, up to 3 days after enrollment</time_frame>
    <description>12-item momentary self-regulation scale that can capture self-regulatory dynamics at a momentary level using a 5 point scale (1 not at all- 5 extremely)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self Regulation Scale</measure>
    <time_frame>4 weeks after enrollment</time_frame>
    <description>12-item momentary self-regulation scale that can capture self-regulatory dynamics at a momentary level using a 5 point scale (1 not at all- 5 extremely)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self Regulation Scale</measure>
    <time_frame>8 weeks after enrollment</time_frame>
    <description>12-item momentary self-regulation scale that can capture self-regulatory dynamics at a momentary level using a 5 point scale (1 not at all- 5 extremely)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimates of Sleep</measure>
    <time_frame>56 days (or 8-weeks)</time_frame>
    <description>Use mobile sensor and phone utilization data to develop individualized estimates of sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimates of Activities</measure>
    <time_frame>56 days (or 8-weeks)</time_frame>
    <description>Use mobile sensor and phone utilization data to develop individualized estimates of activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimates of sociability</measure>
    <time_frame>56 days (or 8-weeks)</time_frame>
    <description>Use mobile sensor and phone utilization data to develop individualized estimates of sociability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimates of Light Exposure</measure>
    <time_frame>56 days (or 8-weeks)</time_frame>
    <description>Use mobile sensor and phone utilization data to develop individualized estimates of light exposure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimates of Screen Time</measure>
    <time_frame>56 days (or 8-weeks)</time_frame>
    <description>Use mobile sensor and phone utilization data to develop individualized estimates of screen time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimates of Heart Rate Variability</measure>
    <time_frame>56 days (or 8-weeks)</time_frame>
    <description>Use mobile sensor and phone utilization data to develop individualized estimates of heart rate variability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimates of Sound Levels</measure>
    <time_frame>56 days (or 8-weeks)</time_frame>
    <description>Use mobile sensor and phone utilization data to develop individualized estimates of sound levels.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Opioid-use Disorder</condition>
  <condition>Anxiety Disorders</condition>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Smartphone Digital Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Smartphone Digital Intervention Group is the experimental group. Participants randomized to this group will download the smartphone intervention and be asked to use the intervention four times per week for four weeks ( 16 digital sessions). The smartphone digital intervention will also continuously collect passive sensing data. The smartphone digital intervention will be designed to treat anxiety and depression by providing informational videos to help participants treat these symptoms. These videos include information about physical activity, muscle relaxation, and other proven helpful interventions to help with anxiety and depression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wait list Control Condition</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The wait list control condition will not receive the digital intervention treatment for the duration of the study. They will still provide urine samples during the study. Participants assigned to this condition will be able to access the digital intervention after their participation in the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Smartphone-Based Digital Intervention</intervention_name>
    <description>The digital intervention will be a prototype, and the current trial will be used to continue to both develop and refine the intervention. The current intervention will be based on a combination of cognitive-behavioral principles. As with prior research, the mobile platform will be delivered via Qualtrics, a HIPAA compliant and mobile-friendly platform. The cognitive-behavioral therapy will be primarily based on components with strongest support in digital interventions. The app will continuously collect passive sensing data on patterns in 1) sleep duration and quality;(2) light (3) location; (4) movement (5) social contact including duration and frequency of incoming and outcoming calls and text messages; (6) screen time; and (7) heart rate variability; (8) sound levels captured through passively collected smartphone The platform will deliver interactive interventions where participants will view texts and images, and it will also allow user interaction.</description>
    <arm_group_label>Smartphone Digital Intervention Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (age 18 or older)&#xD;
&#xD;
          -  fluent in English&#xD;
&#xD;
          -  able to provide informed consent&#xD;
&#xD;
          -  meet current criteria for OUD (as defined by a Rapid Opioid Dependence Screen)&#xD;
&#xD;
          -  are receiving methadone, buprenorphine, and/or naltrexone for OUD&#xD;
&#xD;
          -  meet current criteria for an anxiety and/or depressive disorder (based on the Patient&#xD;
             Health Questionnaire and the Generalized Anxiety Disorder Questionnaire).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  active suicidality&#xD;
&#xD;
          -  psychosis&#xD;
&#xD;
          -  bipolar disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas C Jacobson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natalie X Thomas, B.S.</last_name>
    <phone>4109134746</phone>
    <email>natalie.thomas@dartmouth.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center For Technology and Behavioral Health</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03766</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas C Jacobson</last_name>
      <phone>603-646-7037</phone>
      <email>Nicholas.C.Jacobson@dartmouth.edu</email>
    </contact>
    <investigator>
      <last_name>Nicholas C Jacobson, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Applebaum AJ, Bullis JR, Traeger LN, O'cleirigh C, Otto MW, Pollack MH, Safren SA. Rates of mood and anxiety disorders and contributors to continued heroin use in methadone maintenance patients: A comparison by HIV status. Neurobehav HIV Med. 2010 Aug 10;2010(2):49-57.</citation>
    <PMID>24062619</PMID>
  </reference>
  <reference>
    <citation>Barry DT, Beitel M, Breuer T, Cutter CJ, Savant J, Peters S, Schottenfeld RS, Rounsaville BJ. Group-based strategies for stress reduction in methadone maintenance treatment: what do patients want? J Addict Med. 2011 Sep;5(3):181-7. doi: 10.1097/ADM.0b013e3181ee77cl.</citation>
    <PMID>21841430</PMID>
  </reference>
  <reference>
    <citation>Bartoli F, Carr√† G, Brambilla G, Carretta D, Crocamo C, Neufeind J, Baldacchino A, Humphris G, Clerici M. Association between depression and non-fatal overdoses among drug users: a systematic review and meta-analysis. Drug Alcohol Depend. 2014 Jan 1;134:12-21. doi: 10.1016/j.drugalcdep.2013.10.007. Epub 2013 Oct 24. Review.</citation>
    <PMID>24210424</PMID>
  </reference>
  <reference>
    <citation>Blume, A. W., Schmaling, K. B., &amp; Marlatt, G. A. (2000). Revisiting the self-medication hypothesis from a behavioral perspective. Cognitive and Behavioral Practice, 7(4), 379-384. https://doi.org/10.1016/S1077-7229(00)80048-6</citation>
  </reference>
  <reference>
    <citation>Borkovec TD, Newman MG, Pincus AL, Lytle R. A component analysis of cognitive-behavioral therapy for generalized anxiety disorder and the role of interpersonal problems. J Consult Clin Psychol. 2002 Apr;70(2):288-98.</citation>
    <PMID>11952187</PMID>
  </reference>
  <reference>
    <citation>Childress AR, Ehrman R, McLellan AT, MacRae J, Natale M, O'Brien CP. Can induced moods trigger drug-related responses in opiate abuse patients? J Subst Abuse Treat. 1994 Jan-Feb;11(1):17-23.</citation>
    <PMID>8201629</PMID>
  </reference>
  <reference>
    <citation>Cunningham JA, Hendershot CS, Kay-Lambkin F, Neighbors C, Griffiths KM, Bennett K, Bennett A, Godinho A, Schell C. Does providing a brief internet intervention for hazardous alcohol use to people seeking online help for depression reduce both alcohol use and depression symptoms among participants with these co-occurring disorders? Study protocol for a randomised controlled trial. BMJ Open. 2018 Jul 19;8(7):e022412. doi: 10.1136/bmjopen-2018-022412.</citation>
    <PMID>30030322</PMID>
  </reference>
  <reference>
    <citation>Deady M, Mills KL, Teesson M, Kay-Lambkin F. An Online Intervention for Co-Occurring Depression and Problematic Alcohol Use in Young People: Primary Outcomes From a Randomized Controlled Trial. J Med Internet Res. 2016 Mar 23;18(3):e71. doi: 10.2196/jmir.5178.</citation>
    <PMID>27009465</PMID>
  </reference>
  <reference>
    <citation>Firth J, Torous J, Nicholas J, Carney R, Pratap A, Rosenbaum S, Sarris J. The efficacy of smartphone-based mental health interventions for depressive symptoms: a meta-analysis of randomized controlled trials. World Psychiatry. 2017 Oct;16(3):287-298. doi: 10.1002/wps.20472.</citation>
    <PMID>28941113</PMID>
  </reference>
  <reference>
    <citation>Firth J, Torous J, Nicholas J, Carney R, Rosenbaum S, Sarris J. Can smartphone mental health interventions reduce symptoms of anxiety? A meta-analysis of randomized controlled trials. J Affect Disord. 2017 Aug 15;218:15-22. doi: 10.1016/j.jad.2017.04.046. Epub 2017 Apr 25. Review.</citation>
    <PMID>28456072</PMID>
  </reference>
  <reference>
    <citation>Hassan AN, Howe AS, Samokhvalov AV, Le Foll B, George TP. Management of mood and anxiety disorders in patients receiving opioid agonist therapy: Review and meta-analysis. Am J Addict. 2017 Sep;26(6):551-563. doi: 10.1111/ajad.12581. Epub 2017 Jul 4. Review.</citation>
    <PMID>28675762</PMID>
  </reference>
  <reference>
    <citation>Hogarth L, Hardy L, Bakou A, Mahlberg J, Weidemann G, Cashel S, Moustafa AA. Negative Mood Induction Increases Choice of Heroin Versus Food Pictures in Opiate-Dependent Individuals: Correlation With Self-Medication Coping Motives and Subjective Reactivity. Front Psychiatry. 2019 May 15;10:274. doi: 10.3389/fpsyt.2019.00274. eCollection 2019.</citation>
    <PMID>31156470</PMID>
  </reference>
  <reference>
    <citation>Hyman SM, Fox H, Hong KI, Doebrick C, Sinha R. Stress and drug-cue-induced craving in opioid-dependent individuals in naltrexone treatment. Exp Clin Psychopharmacol. 2007 Apr;15(2):134-43.</citation>
    <PMID>17469937</PMID>
  </reference>
  <reference>
    <citation>Kay-Lambkin FJ, Baker AL, Lewin TJ, Carr VJ. Computer-based psychological treatment for comorbid depression and problematic alcohol and/or cannabis use: a randomized controlled trial of clinical efficacy. Addiction. 2009 Mar;104(3):378-88. doi: 10.1111/j.1360-0443.2008.02444.x.</citation>
    <PMID>19207345</PMID>
  </reference>
  <reference>
    <citation>Kenardy JA, Dow MG, Johnston DW, Newman MG, Thomson A, Taylor CB. A comparison of delivery methods of cognitive-behavioral therapy for panic disorder: an international multicenter trial. J Consult Clin Psychol. 2003 Dec;71(6):1068-75.</citation>
    <PMID>14622082</PMID>
  </reference>
  <reference>
    <citation>Kosten TR, Rounsaville BJ, Kleber HD. A 2.5-year follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts. Arch Gen Psychiatry. 1986 Aug;43(8):733-8.</citation>
    <PMID>3729667</PMID>
  </reference>
  <reference>
    <citation>Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13.</citation>
    <PMID>11556941</PMID>
  </reference>
  <reference>
    <citation>Kroenke, Kurt, &amp; Spitzer, R. L. (2002). The PHQ-9: A new depression diagnostic and severity measure. Psychiatric Annals, 32(9), 509-515. https://doi.org/10.3928/0048-5713-20020901-06</citation>
  </reference>
  <reference>
    <citation>Krupnick JL, Green BL, Amdur R, Alaoui A, Belouali A, Roberge E, Cueva D, Roberts M, Melnikoff E, Dutton MA. An Internet-based writing intervention for PTSD in veterans: A feasibility and pilot effectiveness trial. Psychol Trauma. 2017 Jul;9(4):461-470. doi: 10.1037/tra0000176. Epub 2016 Sep 8.</citation>
    <PMID>27607767</PMID>
  </reference>
  <reference>
    <citation>Lange A, Rietdijk D, Hudcovicova M, van de Ven JP, Schrieken B, Emmelkamp PM. Interapy: a controlled randomized trial of the standardized treatment of posttraumatic stress through the internet. J Consult Clin Psychol. 2003 Oct;71(5):901-9.</citation>
    <PMID>14516238</PMID>
  </reference>
  <reference>
    <citation>Levin ME, Navarro C, Cruz RA, Haeger J. Comparing in-the-moment skill coaching effects from tailored versus non-tailored acceptance and commitment therapy mobile apps in a non-clinical sample. Cogn Behav Ther. 2019 May;48(3):200-216. doi: 10.1080/16506073.2018.1503706. Epub 2018 Aug 17.</citation>
    <PMID>30117784</PMID>
  </reference>
  <reference>
    <citation>Maloney E, Degenhardt L, Darke S, Nelson EC. Are non-fatal opioid overdoses misclassified suicide attempts? Comparing the associated correlates. Addict Behav. 2009 Sep;34(9):723-9. doi: 10.1016/j.addbeh.2009.04.011. Epub 2009 May 3.</citation>
    <PMID>19447563</PMID>
  </reference>
  <reference>
    <citation>Marshall BDL, Green TC, Elston B, Yedinak JL, Hadland SE, Clark MA. The Effectiveness of Internet- and Field-Based Methods to Recruit Young Adults Who Use Prescription Opioids Nonmedically. Subst Use Misuse. 2018 Aug 24;53(10):1688-1699. doi: 10.1080/10826084.2018.1425725. Epub 2018 Jan 24.</citation>
    <PMID>29364768</PMID>
  </reference>
  <reference>
    <citation>McHugh RK, Fitzmaurice GM, Carroll KM, Griffin ML, Hill KP, Wasan AD, Weiss RD. Assessing craving and its relationship to subsequent prescription opioid use among treatment-seeking prescription opioid dependent patients. Drug Alcohol Depend. 2014 Dec 1;145:121-6. doi: 10.1016/j.drugalcdep.2014.10.002. Epub 2014 Oct 16.</citation>
    <PMID>25454409</PMID>
  </reference>
  <reference>
    <citation>Moore MT, Anderson NL, Barnes JM, Haigh EA, Fresco DM. Using the GAD-Q-IV to identify generalized anxiety disorder in psychiatric treatment seeking and primary care medical samples. J Anxiety Disord. 2014 Jan;28(1):25-30. doi: 10.1016/j.janxdis.2013.10.009. Epub 2013 Nov 20.</citation>
    <PMID>24334213</PMID>
  </reference>
  <reference>
    <citation>Newman, M. G., Zuellig, A. R., Kachin, K. E., Constantino, M. J., Przeworski, A., Erickson, T., &amp; Cashman-McGrath, L. (2002). Preliminary reliability and validity of the Generalized Anxiety Disorder Questionnaire-IV: A revised self-report diagnostic measure of generalized anxiety disorder. Behavior Therapy, 33(2), 215-233. https://doi.org/10.1016/S0005-7894(02)80026-0</citation>
  </reference>
  <reference>
    <citation>Pani PP, Vacca R, Trogu E, Amato L, Davoli M. Pharmacological treatment for depression during opioid agonist treatment for opioid dependence. Cochrane Database Syst Rev. 2010 Sep 8;(9):CD008373. doi: 10.1002/14651858.CD008373.pub2. Review.</citation>
    <PMID>20824876</PMID>
  </reference>
  <reference>
    <citation>Stathopoulou G, Pollack MH, Otto MW. Anxiety sensitivity moderates drug cravings in response to induced negative affect in opioid dependent outpatients. Addict Behav. 2018 Sep;84:75-78. doi: 10.1016/j.addbeh.2018.03.020. Epub 2018 Mar 13.</citation>
    <PMID>29631093</PMID>
  </reference>
  <reference>
    <citation>Stein MD, Santiago Rivera OJ, Anderson BJ, Bailey GL. Perceived need for depression treatment among persons entering inpatient opioid detoxification. Am J Addict. 2017 Jun;26(4):395-399. doi: 10.1111/ajad.12554. Epub 2017 Apr 28.</citation>
    <PMID>28453912</PMID>
  </reference>
  <reference>
    <citation>Walker J, Burke K, Wanat M, Fisher R, Fielding J, Mulick A, Puntis S, Sharpe J, Esposti MD, Harriss E, Frost C, Sharpe M. The prevalence of depression in general hospital inpatients: a systematic review and meta-analysis of interview-based studies. Psychol Med. 2018 Oct;48(14):2285-2298. doi: 10.1017/S0033291718000624. Epub 2018 Mar 26.</citation>
    <PMID>29576041</PMID>
  </reference>
  <reference>
    <citation>Watkins KE, Hunter SB, Wenzel SL, Tu W, Paddock SM, Griffin A, Ebener P. Prevalence and characteristics of clients with co-occurring disorders in outpatient substance abuse treatment. Am J Drug Alcohol Abuse. 2004 Nov;30(4):749-64.</citation>
    <PMID>15624547</PMID>
  </reference>
  <reference>
    <citation>Wickersham JA, Azar MM, Cannon CM, Altice FL, Springer SA. Validation of a Brief Measure of Opioid Dependence: The Rapid Opioid Dependence Screen (RODS). J Correct Health Care. 2015 Jan;21(1):12-26. doi: 10.1177/1078345814557513. Erratum in: J Correct Health Care. 2020 Apr;26(2):194.</citation>
    <PMID>25559628</PMID>
  </reference>
  <reference>
    <citation>Wilhelm S, Weingarden H, Ladis I, Braddick V, Shin J, Jacobson NC. Cognitive-Behavioral Therapy in the Digital Age: Presidential Address. Behav Ther. 2020 Jan;51(1):1-14. doi: 10.1016/j.beth.2019.08.001. Epub 2019 Aug 8.</citation>
    <PMID>32005328</PMID>
  </reference>
  <reference>
    <citation>Gratz, K.L., Roemer, L. Multidimensional Assessment of Emotion Regulation and Dysregulation: Development, Factor Structure, and Initial Validation of the Difficulties in Emotion Regulation Scale. J Psychopathol Behav Assess 30, 315 (2008). https://doi.org/10.1007/s10862-008-9102-4</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Trustees of Dartmouth College</investigator_affiliation>
    <investigator_full_name>Nicholas Jacobson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

